source
- AstraZeneca acquires Omniose to boost bacterial vaccine capabilitiesAstraZeneca has completed the purchase of Omniose, a specialist in vaccine bioconjugation, making the company a wholly owned subsidiary of its infectious disease division. The two firms began coll…
- Mirum's hepatitis D antibody brelovitug meets primary endpoint in phase 3 trialMirum Pharmaceuticals announced that its experimental antiviral monoclonal antibody brelovitug achieved the primary efficacy goal in a phase 3 study for hepatitis D. The trial results continue a s…